Issue 2/2020
Content (15 Articles)
Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells
R. Gajendra Reddy, Unis Ahmad Bhat, Sumana Chakravarty, Arvind Kumar
Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
Erjian Wang, Steven G. DuBois, Cynthia Wetmore, Reza Khosravan
A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men
Inderjeet Singh, Ronak Patel, Akash Patel, Vinu Jose
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study
Motoyasu Kan, Hiroshi Imaoka, Kazuo Watanabe, Mitsuhito Sasaki, Hideaki Takahashi, Yusuke Hashimoto, Izumi Ohno, Shuichi Mitsunaga, Kumiko Umemoto, Gen Kimura, Yuko Suzuki, Hiroki Eguchi, Toru Otsuru, Kyosuke Goda, Masafumi Ikeda
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer
Toshio Shimizu, Kazuto Nishio, Kazuko Sakai, Isamu Okamoto, Kunio Okamoto, Masayuki Takeda, Maiko Morishita, Kazuhiko Nakagawa
Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer
Fang-Tao Wang, Hui Wang, Qi-Wei Wang, Mu-Su Pan, Xin-Ping Li, Wei Sun, Yue-Zu Fan
Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration
Tomonobu Uchino, Hiyori Fujino, Daichi Kamiya, Tomonori Suzuki, Yasunori Miyazaki, Kazuhiro Asada, Toshihiro Shirai, Hiroaki Yagi, Yuko Sano, Mutsumi Moriki, Hajime Mizuno, Kenichiro Todoroki, Midori Kimura, Yoshiyuki Kagawa
Cytotoxic and biomechanical effects of clinical dosing schemes of paclitaxel on neurons and cancer cells
Chou-Ching K. Lin, Chih-Hsuan Yang, Ming-Shaung Ju
Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells
Hui Zhang, Haoyu Xu, Ranran Zhang, Xinying Zhao, Ming Liang, Fenggui Wei
A phase Ι study to evaluate the application of photocyanine using pharmacokinetic and pharmacodynamic analysis in patients with malignancy
Su Li, Bingtian Bi, Guangyu Luo, Jing Zhan, Rong Zhang, Jibin Li, Naisheng Chen, Jinling Huang, Jinping Xue, Guoliang Xu
Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
Yosuke Kito, Hironaga Satake, Hiroya Taniguchi, Takeshi Yamada, Yoshiki Horie, Taito Esaki, Tadamichi Denda, Hisateru Yasui, Naoki Izawa, Toshiki Masuishi, Toshikazu Moriwaki, Keita Mori, Kentaro Yamazaki
A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)
Hironori Samura, Eiji Oki, Hiroshi Okumura, Takefumi Yoshida, Seiichiro Kai, Kazuma Kobayashi, Tatsuya Kinjo, Shinichiro Mori, Tetsuo Tohyama, Kippei Ohgaki, Hirofumi Kawanaka, Akitaka Makiyama, Norio Ureshino, Masahito Kotaka, Takayuki Shimose, Koji Ando, Hiroshi Saeki, Hideo Baba, Yoshihiko Maehara, Masaki Mori
HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer
Jiahong Jiang, Shaohai Wang, Zehua Wang, Jing Cai, Lingling Han, Lisha Xie, Qing Han, Wenwen Wang, Yifan Zhang, Xiaoqi He, Chun Yang
Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
Ken Ogasawara, Christine Xu, Vanaja Kanamaluru, Nicholas Siebers, Sekhar Surapaneni, Laurence Ridoux, Maria Palmisano, Gopal Krishna
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
Hisanaga Nomura, Daiki Tsuji, Ken Demachi, Nobuo Mochizuki, Haruki Matsuzawa, Tomonori Yano, Hiroyuki Daiko, Satoshi Fujii, Takashi Kojima, Kunihiko Itoh, Toshikatsu Kawasaki